[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neoplasms-rectal\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neoplasms-rectal":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":5},"100329789","biomarkers-for-predicting-neoadjuvant-chemoradio-resistance-for-middle-low-advanced-rectal-cancer-100329789",false,"NCT03573791","Biomarkers for Predicting Neoadjuvant Chemoradio-resistance for Middle-low Advanced Rectal Cancer","Identification of Tissue Biomarkers for Predicting Neoadjuvant Chemoradio-resistance in Patients With Middle-low Local Advanced Rectal Cancer.","Inclusion Criteria:\n\n* Histopathology proved to be adenocarcinoma of the rectum.\n* The edge of tumor is within 12cm of anus margin.\n* According to the eighth edition of AJCC TNM staging standard ,that staging for Ⅱ-Ⅲ period, as T3-T4, N0 or any T, N1-2.\n* There is no history of chemotherapy, radiotherapy or immunotherapy before neoadjuvant therapy.\n* Understand and agree to sign the informed consent for the study.\n\nExclusion Criteria:\n\n* With intestinal obstruction or impending obstruction, or perforation.\n* With other malignancies occurred within 5 years.","ALL","18 Years","75 Years",{"count":20,"type":21},152,"ESTIMATED","OBSERVATIONAL","Neoadjuvant therapy has been widely applied to locally advanced rectal cancer. However, about 50% of patients receiving this therapy do not respond well as evidenced by the fact that their T or N stages are not effectively decreased judged by postoperative pathological examination. The purpose of this trail is to identify the biomarkers (from within patients' tumor mass before neoadjuvant therapy) to predict resistance to neoadjuvant therapy. These biomarkers can help stratify neoadjuvant-resistant patients towards surgery while avoiding unnecessary chemoradio-based neoadjuvant therapy.",[25,26,27,28,29,30,31],"Rectal Cancer","Cancer of Rectum","Cancer of the Rectum","Neoplasms, Rectal","Rectal Tumors","Rectum Cancer","Rectum Neoplasms","RECRUITING","2026-08-17",{"date":35,"type":36},"2026-08-18","ACTUAL",{"date":38,"type":36},"2018-05-21",{"date":40,"type":21},"2028-05-21",{"name":42,"class":43},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":4},"100650014","phase-3-a-study-of-the-duration-of-dostarlimab-in-untreated-mismatch-repair-deficient-dmmr-microsatellite-instability-high-msi-h-locally-advanced-rectal-cancer-100650014","NCT07740720","A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)\u002F Microsatellite Instability-high (MSI-H) Locally Advanced Rectal Cancer","A Phase 3b, Open-label Study Investigating the Duration of Neoadjuvant Dostarlimab Monotherapy in Participants With Untreated Stage II\u002FIII dMMR\u002FMSI-H Locally Advanced Rectal Cancer","DuraSTAR","Inclusion Criteria:\n\n* Has histologically confirmed Stage II to III (T3-T4, N0, or T any, N+) locally advanced rectal adenocarcinoma.\n* Has radiologically and endoscopically evaluable disease.\n* Has a tumor demonstrating the presence of either:\n\n  1. dMMR status; MMR status must be assessed by immunohistochemistry for MMR protein expression (MLH1, MSH2, MSH6, PMS2) where loss of 1 or more proteins indicates dMMR; MMR status will be determined locally; or\n  2. MSI-H phenotype as determined by polymerase chain reaction or by tissue next generation sequencing; MSI-H will be determined locally.\n* Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Has adequate organ function.\n\nExclusion Criteria:\n\n* Has received prior radiation therapy, systemic therapy, or surgery for management of rectal cancer.\n* Has a tumor that, in the investigator's judgment, is causing symptomatic bowel obstruction or otherwise requires urgent\u002Femergent local intervention. Participants with a history of bowel obstruction are eligible after obstruction is relieved by a diverting stoma (defunctioning colostomy). Patients with a history of bowel obstruction in the context of current rectal cancer diagnosis and treated with stenting are not eligible.\n* Has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment.\n* Has undergone any major surgical procedure, open biopsy, or experienced significant traumatic injury within 28 days prior to enrollment.\n* Is receiving any other anticancer or experimental therapy.",{"count":53,"type":21},90,"INTERVENTIONAL",[56],"PHASE3","This study is conducted in adults with rectal cancer that has a certain genetic type. The main goal is to find out whether a longer treatment period with dostarlimab can help more participants have a complete response to treatment and avoid standard treatments like chemotherapy, radiation treatment, or surgery. Scans and endoscopy tests will be conducted to see if the tumor disappears and how long the cancer stays under control. The study will also collect information on side effects and health outcomes after dostarlimab.",[28],[60,61,62,63,64,50,65,66,67],"GSK4057190","Dostarlimab","dMMR","MSI-H","Locally advanced rectal cancer","PD-1","LARC","Anti-PD1","NOT_YET_RECRUITING","2026-07-24",{"date":71,"type":36},"2026-08-03",{"date":73,"type":21},"2026-09-17",{"date":75,"type":21},"2029-12-31",{"name":77,"class":78},"GlaxoSmithKline","INDUSTRY"]